多基因风险评分与类风湿关节炎患者影像学进展的相关性
本研究利用类风湿关节炎(RA)易感性全基因组关联研究(GWAS)数据构建多基因风险评分,在训练集500例和测试集740例RA患者中评估其预测5年内Sharp/van der Heijde评分(SHS)进展的能力。结果显示,由43,784个单核苷酸多态性构建的多基因风险评分在严重影像学进展与非严重进展患者间存在显著差异,最高五分位组严重进展风险高于最低五分位组(OR 1.90)。多变量分析表明多基因风险评分、女性、ACPA阳性和体重指数是严重影像学进展的独立风险因素。
要点
- 多基因风险评分最高五分位组较最低五分位组严重影像学进展风险更高(OR 1.90,P=0.0022)。
- 在发病年龄较轻的患者中,多基因风险评分与严重进展的关联更强(OR 5.06,P=0.00038)。
- 多基因风险评分、女性、ACPA阳性和体重指数为严重影像学进展的独立风险因素。
核心结论
- 基于RA易感性GWAS数据的多基因风险评分与RA患者影像学进展的严重程度相关。
研究设计与样本
- 利用RA易感性GWAS汇总数据构建多基因风险评分,并在训练集(n=500例RA患者)中评估模型选择、在测试集(n=740例RA患者)中验证。
- 评估RA发病后最初5年SHS变化,按四分位数分层,最高四分位定义为严重影像学进展(评分变化>35分),其余3个四分位为非严重进展。
主要发现
- 由43,784个单核苷酸多态性构建的多基因风险评分在严重影像学进展与非严重进展患者间存在显著差异:训练集P=0.0064,测试集P=0.017。
- 多基因风险评分最高五分位组较最低五分位组严重进展风险更高(OR 1.90,P=0.0022)。
- 在发病年龄较轻的患者中,多基因风险评分最高五分位组严重进展风险更高(OR 5.06,P=0.00038)。
- 多基因风险评分最高五分位组和ACPA阳性组分别较其余组严重影像学进展患者比例显著更高(P=0.00052和P=0.0022)。
- 多变量分析显示多基因风险评分(P=0.00019)、女性(P=0.0033)、ACPA阳性(P=0.0023)和体重指数(P=0.024)为严重影像学进展的独立风险因素。
关键数值与推荐
- 严重影像学进展定义为5年内SHS变化>35分(最高四分位),其余3个四分位为非严重进展。
- 多基因风险评分按显著性水平分为五分位(从最高五分位到最低五分位)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether polygenic risk scores obtained using data from a genome-wide association study (GWAS) of rheumatoid arthritis (RA) susceptibility can be predictors of radiographic progression. METHODS: We constructed polygenic risk scores using GWAS summary data on associations of single-nucleotide polymorphisms with RA susceptibility. The polygenic risk scores were stratified into quintiles based on levels of significance (ranging from top quintile of polygenic risk scores to bottom quintile). In addition, change in the Sharp/van der Heijde score (SHS) of radiographic progression over the first 5 years after onset of RA was assessed. The change in SHS over 5 years was stratified according to quartiles, with the top quartile of change in SHS defined as severe radiographic progression (score change of >35 points) and the remaining 3 quartiles defined as nonsevere radiographic progression. Polygenic risk scores were assessed for their ability to predict the SHS status over 5 years in a training set (n = 500 RA patients) for selection of the best model, and in a testing set (n = 740 RA patients) for validation of the data. We evaluated the performance of the polygenic risk score as a predictor of severe radiographic progression in univariable and multivariable analyses with inclusion of other factors. RESULTS: Polygenic risk scores constructed from 43,784 single-nucleotide polymorphisms significantly differed between patients who experienced severe radiographic progression and those with nonsevere radiographic progression in both the training set (P = 0.0064) and the testing set (P = 0.017). Patients with polygenic risk scores in the top quintile had a higher risk of severe progression compared to those with polygenic risk scores in the bottom quintile (odds ratio [OR] 1.90, P = 0.0022), and the risk of severe radiographic progression was even higher when restricted to patients who were younger at disease onset (OR 5.06, P = 0.00038). The group with polygenic risk scores in the top quintile and the anti-citrullinated protein antibody (ACPA)-positive group had significantly higher proportions of patients with severe radiographic progression (P = 0.00052 and P = 0.0022, respectively) compared to the remaining groups. Multivariable analysis showed that polygenic risk score (P = 0.00019) as well as female sex (P = 0.0033), ACPA positivity (P = 0.0023), and body mass index (P = 0.024) were independent risk factors for severe radiographic progression. CONCLUSION: A polygenic risk score that is derived from GWAS data on RA susceptibility is associated with the level of severity of radiographic progression in patients with RA.
引用
- Honda S, Ikari K, Yano K, et al. Association of Polygenic Risk Scores With Radiographic Progression in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2022. PMID: 35048562. doi:10.1002/art.42051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。